Free Trial
NASDAQ:TPST

Tempest Therapeutics Q4 2024 Earnings Report

Tempest Therapeutics logo
$7.03 +0.04 (+0.63%)
As of 10:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tempest Therapeutics EPS Results

Actual EPS
-$4.03
Consensus EPS
-$3.12
Beat/Miss
Missed by -$0.91
One Year Ago EPS
N/A

Tempest Therapeutics Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tempest Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Tempest Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Tempest Therapeutics Earnings Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More Tempest Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email.

About Tempest Therapeutics

Tempest Therapeutics (NASDAQ:TPST), a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

View Tempest Therapeutics Profile

More Earnings Resources from MarketBeat